RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy to treat tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy foraging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration. It is also developing DermaPrecise, a dermal injection device. The company has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01, RCT-01, and DermaPrecise. RepliCel Life Sciences Inc. is based in Vancouver, Canada.
Frequently asked questions
What sector does RepliCel Life Sciences Inc (RP) operate in?
RepliCel Life Sciences Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is RepliCel Life Sciences Inc (RP) current stock price?
As of the latest data, RepliCel Life Sciences Inc stock price is CA$0.02, with a previous close of CA$0.02.
What is RepliCel Life Sciences Inc (RP) current market capitalization?
RepliCel Life Sciences Inc market cap is approximately 1.10 million.
What is RepliCel Life Sciences Inc (RP) Earnings Per Share (EPS)?
The trailing EPS is -CA$0.02.
Does RepliCel Life Sciences Inc (RP) pay dividends?
No. RepliCel Life Sciences Inc does not pay a dividend.
What is RepliCel Life Sciences Inc (RP) beta (volatility) score?
RepliCel Life Sciences Inc has a beta of 1.016, meaning its volatility is roughly in line with the market.
